Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (CAS 170851-70-4) with high selectivity for the GHS-R1a receptor, designed to stimulate GH release without elevating cortisol or prolactin. It is supplied as lyophilized powder in vials (2 mg, 5 mg, 10 mg) for research use, with purity >99% and storage stability up to 24 months. 

KEY FEATURES 

Selective GH release: Stimulates pulsatile growth hormone secretion via GHS-R1a receptor.

Minimal off-target effects: Does not significantly raise cortisol, prolactin, or ACTH.

Synergistic action: Works well in combination with GHRH analogs (e.g., CJC-1295).

Short half-life: ~2 hours, supporting controlled GH pulses.

High purity: >99% lyophilized peptide, suitable for laboratory research.

Stability: Lyophilized form stable at room temperature up to 24 months; reconstituted solution stable 4–6 weeks refrigerated.

TECHNICAL SPECIFICATIONS 

Chemical Name: Ipamorelin acetate

Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Molecular Formula: C₃₈H₄₉N₉O₅

Molecular Weight: 711.85 Da

CAS Number: 170851-70-4

Appearance: White lyophilized powder

Solubility: Bacteriostatic water, dilute acetic acid, saline

Storage:

Lyophilized: Room temperature (≤24 months)

Reconstituted: 2–8°C (≤6 weeks), protect from light, do not freeze

AVAILABLE CONFIGURATIONS

Ipamorelin should be cataloged under its generic name with identifiers (CAS 170851-70-4, NNC 26-0161, peptide sequence) and configurations (2 mg, 5 mg, 10 mg vials, 2-20mg capsules, bulk powder). It is a high-purity, selective GH secretagogue with strong research relevance but no approved pharmaceutical brand.